| Title |
New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review
|
|---|---|
| Published in |
Infectious Diseases and Therapy, October 2017
|
| DOI | 10.1007/s40121-017-0173-y |
| Pubmed ID | |
| Authors |
Joop E. Arends, Faydra I. Lieveld, Shazaad Ahmad, Andrew Ustianowski |
| Abstract |
Although current therapies can be successful at suppressing hepatitis B viral load, long-term viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with nucleoside/nucleotide analogues have not resulted in any major paradigm shift. An improved understanding of the hepatitis B virus (HBV) lifec ycle and virus-induced immune dysregulation has, however, revealed many potential therapeutic targets, and there are hopes that treatment of hepatitis B could soon be revolutionized. This review summarizes the current developments in HBV therapeutics-both virus directed and host directed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 15% |
| Student > Ph. D. Student | 5 | 12% |
| Student > Master | 5 | 12% |
| Other | 4 | 10% |
| Student > Postgraduate | 3 | 7% |
| Other | 9 | 22% |
| Unknown | 9 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 20% |
| Biochemistry, Genetics and Molecular Biology | 6 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 15% |
| Agricultural and Biological Sciences | 3 | 7% |
| Chemistry | 3 | 7% |
| Other | 4 | 10% |
| Unknown | 11 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2017.
All research outputs
#14,366,847
of 23,006,268 outputs
Outputs from Infectious Diseases and Therapy
#368
of 699 outputs
Outputs of similar age
#181,925
of 327,865 outputs
Outputs of similar age from Infectious Diseases and Therapy
#7
of 10 outputs
Altmetric has tracked 23,006,268 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 699 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,865 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.